- A year marked by significative strategic investments and by
the first sale of the Ikoniscope20 solution, including newly added
reagents in partnership with Empire Genomics, to the first US
customer, validating the Ikonisys business model and paving the way
for accelerated business development
- Acceleration of the commercialization and R&D strategy
to lay the groundwork for sales growth:
- Appointment of Gabriel Plan as Sales Director in France
- Successful installation of the Ikoniscope20 at Toma Advanced
Biomedical Assays (Busto Arsizio, VA, Italy) which will act as a
reference laboratory for R&D and marketing
- Partnership with Evosciences Leasing to support international
expansion
- Establishment of a contract for research activities with
Politecnico di Milano, in the field of machine learning and
bioengineering
- Announcement of the preliminary results of the collaboration
with University of Connecticut (UConn), showing the capability of
the Ikoniscope20 in the detection of rare cells possibly at a
superior rate to that provided by current standards of
immuno-oncology testing
- Partnership with Empire Genomics to expand the portfolio of
optimized probes, in order to meet the needs of Ikoniscope20
customers for high-performance testing;
- Signing of a distribution partnership with BioVendor Laboratory
Medicine for the distribution of the Ikoniscope20 system in Eastern
Europe
- Installation of the Ikoniscope20 solution in a U.S. urology
laboratory that is part of a leading national health care delivery
group
- Launch of the Ikoniscope20max, instrument dedicated to
high-volume customers,
- Establishment of a collaboration with Integrated Gulf
Biosystems Group for distribution of the Ikoniscope20 System in the
Middle East Market (Subsequent event, post December 30, 2022)
Regulatory News:
Ikonisys SA (Code ISIN: FR00140048X2 / Ticker: ALIKO), a
company specializing in the early and accurate detection of cancer
with a unique and fully-automated solution for medical diagnostic
labs, today announced its annual audited results for the year
ending December 31, 2022, as approved by the Board of Directors on
April 28, 2023 and provided an update on its latest
developments.
Mario Crovetto, CEO of Ikonisys, said: “2022 has been
another very important year for our company. In the initial part of
the year we started to commercialize Ikoniscope20, our fully
automated solution for molecular diagnostics, used especially by
pathology laboratories for oncological FISH testing. In December we
announced availability of Ikoniscope20max, the Ikoniscope version
that is particularly adapt for laboratories that process high
volumes. In addition to proceeding with implementation of our
commercial strategy we further strengthened our technology platform
through targeted R&D programs. In particular we are working in
the very promising CTC sector for early cancer detection and
treatment monitoring. Moreover, we continue to update and expand
our application portfolio and to integrate artificial intelligence
into our platform. In short, during 2022 and early 2023 Ikonisys
consistently progressed along the path outlined at the time of our
July 2021 IPO and has efficiently laid the groundwork for sales
growth.”
2022 Full-year results vs. 2021 - Simplified consolidated
income statement audited
Euros
FY 2022
FY 2021
Net Sales
616,866
365,144
Other income
318,352
177,557
Cost of goods sold
(183,413)
(70,642)
Operating expenses
(3,383,538)
(1,036,291)
Operating income / (loss)
(2,638,132)
(564,232)
Financial income / (loss)
(13,537)
(5,107)
Taxes
-
(1,931)
Net income / (loss)
(2,448,320)
(571,269)
Cash and cash equivalents at end of
year
93,985
1,516,526
Details of the main changes in the financial
statements
Net sales for the period ending on December 31, 2022 amounted to
€617k, compared to €365k for the period ending December 31, 2021, a
strong increase of 69% thanks to the initial sales of the
Ikoniscope20 especially in the US.
The increase of the operating expenses is mainly linked to
R&D projects related to the Ikoniscope20 and to sales &
marketing. As far as R&D expenses are concerned, until last
year they were capitalized, while starting from 2022 they are
amortized in parallel with revenues starting to be generated by the
specific R&D projects. As far as Sales & Marketing expenses
are concerned, the increase is mainly due to the recruitment of new
employees and the initiation of marketing activities.
Taking into account the above elements, the operating result is
€-2.7m versus €-0.4m in 2021.
The consolidated cash position as of December 31, 2022 amounts
to €94k, compared to €1.5m as of December 31, 2021. It should be
noted that this position does not include the financing facility
for a total amount up to €5.1m established with Atlas Capital
Markets on October 5, 2022.
Strategy and outlook
Ikonisys plans to accelerate its commercialization strategy
capitalizing on the marketing efforts started in 2022. The company
continues its direct sales & marketing activities with new
prospects in the US and top EU countries. In addition, it is
actively engaging in the establishment of additional distribution
agreements to add to the existing portfolio of partners in order to
expand its global reach of prospective customers.
Moreover, Ikonisys will leverage on its strong network of
development partners in order to address new markets segments, such
as Circulating Tumor Cells (CTC) and immune-oncology. These
prestigious partners include Sheba Medical Center in Tel Aviv and
Tomalab in Milano (circulating tumor cells) and University of
Connecticut (immune-oncology).
Finally, the company is continuing to focus on technological
innovation, notably the use of artificial intelligence (AI) in
medical diagnostics. In particular, the company is progressing in
deep learning based image analysis in order to finalize the next
generation Ikoniscope solution, Ikoniscope AI for personalized
medicine.
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230429005029/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024